文献速递头颈部肿瘤放疗放疗物理与技术姑息放疗与转移瘤

CT引导放射性碘-125粒子植入治疗外照射放疗后复发头颈部癌的疗效及预后因素

The Effectiveness and Prognostic Factors of CT-Guided Radioactive I-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer After External Beam Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-02

分析101例放疗后复发头颈部癌患者接受CT引导放射性碘-125粒子植入的资料,中位既往外照射累积剂量66 Gy,术后D90中位117 Gy。5年局部控制率26.6%,5年总生存率15.5%;D90≥120 Gy者5年局部控制率44.2%,D90<120 Gy者为11.5%(P=.001)。非鳞癌、小病灶和高D90与更好局部控制相关。

要点

  • 101例放疗后复发头颈部癌行CT引导碘-125粒子植入,5年局部控制率26.6%、总生存率15.5%。
  • D90≥120 Gy者5年局部控制率44.2%,D90<120 Gy者11.5%(P=.001)。
  • 非鳞癌、小病灶体积和高D90与更好局部控制相关; Karnofsky体能状态和病灶体积与生存相关。

核心结论

  • 放射性碘-125粒子植入治疗放疗后复发头颈部癌显示出可接受的疗效和安全性。
  • 非鳞癌、小病灶体积和高剂量(D90)与更好的局部控制相关。

研究设计与样本

  • 回顾性分析101例放疗后复发头颈部癌接受CT引导放射性碘-125粒子植入的患者资料。
  • 中位既往累积外照射剂量为66 Gy,术后90%靶区剂量(D90)中位为117 Gy。
  • 短期疗效采用实体瘤疗效评价标准1.1版评估,不良事件采用常见不良事件评价标准4.0版评估。

主要发现

  • 5年局部控制率为26.6%,5年总生存率为15.5%。
  • 单因素分析显示与局部控制率相关的因素包括年龄、病理类型、植入部位、病灶体积和D90。
  • D90<120 Gy者5年局部控制率为11.5%(原文标注为2年),D90≥120 Gy者为44.2%(P=.001)。
  • 多因素分析显示病理类型、病灶体积和D90是局部控制的独立相关因素(P分别为.002、0、.014);Karnofsky体能状态和病灶体积是生存的独立相关因素(P分别为.021和0)。
  • 不良反应包括皮肤或黏膜溃疡26例(25.7%)、疼痛14例(13.9%)、口干2例(2%);未发现毒性反应与剂量的相关性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the efficacy and safety of radioactive I-125 seed implantation in the treatment of recurrent head and neck tumors after radiation therapy. METHODS AND MATERIALS: The data of 101 patients with recurrent head and neck cancer after radiation therapy who received computed tomography guided radioactive I-125 seed implantation were analyzed. The median previous cumulative external irradiation dose was 66 Gy, and the median dose to 90% of the target volume (D90) after operation was 117 Gy. The short-term efficacy was evaluated by Response Evaluation Criteria in Solid Tumors version 1.1, and the adverse event was evaluated by Common Terminology Criteria for Adverse Events version 4.0. RESULTS: The 5-year local control rate was 26.6%, and the 5-year overall survival rate was 15.5%. Univariate analysis showed that factors related to local control rate included age, pathologic type, implantation site, lesion volume, and D90. The 5-year local control rate was 11.5% (2-year) if D90 was <120 Gy and 44.2% if D90 was ≥120 Gy (P = .001). Multivariate analysis showed that pathologic type, lesion volume, and D90 were independent factors related to local control (P = .002, 0, .014, respectively); Karnofsky performance status and lesion volume were independent factors associated with survival (P = .021 and 0, respectively). For the side effects, there were 26 cases of skin or mucosa ulceration (25.7%), 14 cases of pain (13.9%), and 2 cases of dry mouth (2%). The correlation between toxicity and dose had not been found. CONCLUSIONS: Radioactive I-125 seed implantation in the treatment of recurrent head and neck cancer after radiation therapy showed acceptable efficacy and safety. Nonsquamous carcinoma, small lesion volume, and high dose (D90) were correlated with better local control.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ji Z, Jiang Y, Tian S, et al. The Effectiveness and Prognostic Factors of CT-Guided Radioactive I-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer After External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30391521. doi:10.1016/j.ijrobp.2018.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。